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Abstract: Transforming growth factor-beta Eqdc-~F exhibilS strong antiproliferative effects upon lympho-
cytes and inhibits many of the effector functions of activated immune cells. However. Its influence on 
the inducllve phase of immune responses, and in particular its effect on antigen-presenting cells (APC), 
has not been well studied. In this investigation, we examined the influence of human qdc-~ I on the 
antigen-presenting function of human bone marrow (BM)-derived APC propagated in liquid culrure for 
11-17 days in response to granUlocyte/macrophage colony-stimulating factor (GM-CSF). These cells were 
predominantly macrophages, accompanied by a minor population of dendritic cells. qdc-~ I had no effect 
upon the allostimulatory function of vertebral body whole BM cells cultured for 3-5 days in GM-CSF. 
However, it markedly reduced the allostimulatory capacity of 8M-derived APC exposed to the cytokine 
for the last :1 days of cu Iture. This inhibitory action could not be ascribed to cytokine ·carry-over·, or to 
any consistent changes in the expression of cell surface molecules implicated in antigen presentation 
(HLA-OR), intercellular adhesion (ICAM-I; C054). or costimulatory activity (87-1: COSO). Mechanisms 
that may underlie the inhibitory action of TGF·f3 on APC function and the immunologic and possible 
clinical implications of the findings are discussed. 
[troduction its effects depends on several parameters, including cell type, 
differentiation, local environment, and the presence of other 
growth factors and cytokines. The immunomodulatory activi-
ties ofTGF-(3 have been extensively described. ' -6 It has strong 
antiproliferative effects on lymphocytes,6-9 and downregulates 
interferon-gamma (IFN--y)-induced cell surface major histo-
compatibility complex (MHC) class [[ antigen expression.'o 
qdc-~ decreases the expression of many cytokines including 
lFN--y, tumor necrosis factor-alpha and interleukins IL-I, lL-
2 and IL-3. In contrast, it increases production of IL-l receptor 
antagonist,"·.f-6·11 an observation consistent with its anti-
inflammatory properties. qdc-~ inhibits lL-2 receptor 
expression 4 .s anJ the effector functions of activated cells, such 
.tnsforming growth factor-beta (TGF-(3) is a growth inhibi-
y cytokine that exerts multiple actions on most cells. It 
lyS an important role in the regulation of immune reactivity, 
lund healing, and tissue development.l.! Three isoforms of 
;F-(3 have been identified, each encoded by its own gene, 
J with a sequence homology of 70-80%. I The nature of 
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the cytolytic actIvity of NK (natural killer) and LAK 
lmphokine-activated killer) cells.7•9 It deactivates differen-
lied macrophages. suppressing the respiratory burst and H!O! 
lease. l ! However. its effects on the inductive arm of the 
lmune response (i.e. antigen presentation and lymphocyte 
tivation) have not been well characterized. 
The bone marrow (BM) contains a number of cells with the 
ltential to develop into or serve as antigen-presenting cells 
\PC).13.14 These cells are of interest both in the context of 
\I( transplantation and rejection. and with regard to the aug-
entation of donor leukocyte chimerism by BM infusion at 
e time of solid organ transplantation. I' Among the potential 
PC resident in the BM are B lymphocytes. monocytes and 
:ndritic cells. It has been postulated that donor BM-derived 
PC could playa key role in the establishment of tolerance 
lIowing organ transplantation. I6-18 Furthermore. recognition 
at the relative tolerogenicity of the transplanted liver could 
: related to its rich endowment of BM-derived leukocytes l6 
IS led to clinical trials using BM to augment donor cell chim-
ism in solid organ transplantation." BM is a rich source 
Jm which large numbers of APC may be propagated. The 
aturation and function of these cells is markedly affected 
, the cytokine milieu. Thus, it has recently been shown that 
anulocyte/macrophage colony-stimulating factor (GM-CSF). 
ther alone or in combination with other cytokines. promotes 
e maturation and development both of macrophages and den-
'itic cells. I 9-22 
>bjective 
he objective was to explore the inffuence of qdc-~ I on the 
'owth and allostimulatory activity of cells present in unmodi-
~d human vertebral body BM. and in APC-enriched popu-
tions grown in response to recombinant (r) human (h) GM-
SF. The cells were tested using both naive and primed T cells 
responders and characterized with a panel of monoclonal 
ltibodies (mAbs) directed against key cell surface phenotypic 
ld functional markers. 
laterials and methods 
reparation. culture and treatment of BM cells 
~rmission to use BM from human cadaveric organ donors for 
search purposes was obtained from the donor family as per 
niversity of Pittsburgh Medical Center Internal Review 
oard protocol. Thoracolumbar vertebral bodies were pro-
:ssed as described elsewhere.1 S BM cell suspensions were 
~eparedK and erythrocytes lysed with sterile water for 3 s. 
ysis was quenched with an appropriate volume of 
)x Hanks' Balanced Salt Solution (HBSS; Gibco BRL. 
rand Island. NY) to render the final suspension isotonic. The 
:Ils were then washed twice with HBSS. sia~i1ity was con-
rmed by trypan blue dye exclusion. The cells were resus-
'!nded in RPMI-1640 (Gibco BRL) supplemented with 5% 
<Iv) human AB serum (Nalgene. Miami. FL). nonessential 
:nino acids. sodium pyruvate. L-glutamine. penicillin-strepto-
lycin. 2-mercaptoethanol (all from Gibco BRL). and 
.4 ngiml rhGM-CSF (R&D Systems. Minneapolis. MN). Two 
106 cells were placed in each well of a 24 well plate in 
volume of 2 ml. The cultures were maintained at 37°C in 
umidified 5% Cl~ in air. and fed every other day by aspirat-
ransplant Immunology 1996: 4: \86-19\ 
ing half of the supernatant and then replenishing the wells 
with an equivalent volume of fresh. GM-CSF-supplemented 
medium. To enrich for APC, the plate were swirled gently 
prior to aspiration to remove nonadherent granulocytes, with-
out dislodging clusters of presumptive dendritic cell progeni-
tors attached loosely to monolayers of plastic-adherent macro-
phages.19.n For cultured whole BM. no attempt was made to 
remove nonadherent cells over the 3-5 day culture period. The 
cultures Were inspected daily and. when growing clusters of 
cells were abundant (at 8-14 days), subcultures were perfor-
med. 
The mature 25 kDa dimer of rhqdc-~ I (R&D Systems; 
0.6 nglml) was added to selected plates. The cells were cul-
tured for an additional 3 days and then harvested by pipetting. 
They were washed three times in a large excess of HBSS to 
remove any free contaminating cytokines. Decanted super-
natants were saved for later analysis. Harvested cells. which 
consisted of those easily dislodged by pi petting. were used in 
functional assays and immunophenotypic analysis. Cytospin 
preparations were stained with Giemsa to demonstrate cell 
morphology. 
mAbs 
Mouse mAbs to the following human cell surface antigens 
were used: Leu-4 (T cell; CD3 epsilon chain). Leu-3a (T 
helper/inducer; CD4). Leu-2a (T suppressor/cytotoxic; CDS), 
Leu-19 (NK cell: CD56). Leu-12 (B cell; CDI9). Leu-M3 
(macrophage: CDI4). Hle-l (leukocyte common antigen, 
LCA: CD45). HLA-DR (MHC class II). COlla (LFA-Ia), 
Leu-IS (CR); CDllb), Leu-M5 (CR4 ; CDllc). CDIS (LFA-
f~FK Leu-Sb (LFA-2; CD2). CDSO (BBIIB7) (all Becton 
Dickinson, San Jose. CA); T6-RDI (CDla) (Coulter Immu-
nology. Hialeah. FL); CD54 (ICA.M-I) (PharMingen. San 
Diego, CA). 
Staining of cell surface antigens 
Immunophenotypic analysis was performed by cytoffuorogra-
phy. using a FACScan ffow cytometer (Becton Dickinson. 
Mountain View. CA). Cells harvested from human BM cul-
tures were stained with the appropriate mouse IgG isotypic 
subclass controls to detect the presence of nonsPecific antibody 
staining. Two x 10' cells per sample were first blocked with 
10% (v/v) normal goat serum (Vector Labs. Burlingame. CA) 
in HBSS containing 0.1 % bovine serum albumin (BSA; 
Sigma. St Louis. ~lF for 30 min at 4°C. Cells were then 
washed once with 0.1 % BSNHBSS and centrifuged at 
400 x g. 4°C for 6 min. Supernatants were decanted and the 
cells resuspended in 100 JLI. They were then stained with 
FITC- or phycoerythrin-conjugated mouse mAbs for 45 min 
at 4°C, Excess antibody was removed by washing twice in 
0.1 % BSNHBSS. Samples were fixed in 1% paraformal-
dehyde (Sigma) prior to analysis. Typically, 5000 events were 
analyzed from each sample. Cells were analyzed by gating on 
the large. granular population. 
Functional assays 
The allostimulatory activity of whole BM cells and APC-
enriched BM-derived populations was tested in primary mixed 
lymphocyte reactions (MLR) and pooled primed lymphocyte 
tests (PL n. Cultured cells 'Y-irradiated with 20 Gy served as 
stimulators. Cryopreserved donor-derived splenocytes were 
irradiated to serve as positive controls. For use as responders 
in MLR. peripheral blood lymphocytes (PBL) were isolated 
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.-om heparinized blood of normal healthy donors by centrifug-
tion over Ficoll-Hypaque. Six-day unidirectional MLR cul-
lres were established with a fixed number of PBL responders 
I x 10' cells per well) and varying numbers of irradiated 
:imulators. Triplicate cultures were performed in 96 well 
lates. in 200 ~f of tissue culture medium supplemented with 
% (v/v) human AB serum. at 37°C. in a humidified atmos-
here of 5% COl in air. During the final 18 h of incubation. 
1ch culture was labeled with I ~Ci of [3H]thymidine (ICN 
adiochemicals. Costa Mesa. CA). Cells were harvested onto 
lass fiber disks using a multiple cell harvester. and the degree 
f thymidine incorporation was determined in a liquid scintil-
tion counter. To test for qdc-~ 1 'carry over'. supernatants 
om washed cells were added to lymphocytes stimulated by 
Jnor spleen cells at the initiation of culture. Thymidine 
;>take was measured during the last 18 h of culture. 
For the PL T. PBL from healthy donors were primed by a 
rge. pooled panel of irradiated cells of different HLA types 
looled PL T reagent). Alloreactive lymphocytes served as 
sponders in a secondary assay using irradiated BM-derived 
PC as stimulators. The number of responders was fixed at 
5 x 104 cells per well. while the number of stimulators was 
lIied. Cultures were performed in triplicate (200 ~f per well). 
96 well plates. for 3 days and [3Hlthymidine uptake was 
sessed as described above. 
tatistics 
atistical analysis was performed using paired f-tests on Stat-
ew 4.0.1 software (Abacus Concepts. Berkeley, CA). A p 
due < 0.05 was considered significant. 
:esults 
ffects of TGF-f31 on the growth and morphologic 
Jpearance of GM-CSF stimulated 8M-derived 
PC 
total of 4.8 x 10' whole BM cells were placed initially in 
ch culture plate (2 x 106 cells per well in a 24 well plate). 
:ter extended culture in GM-CSF for 11-17 days. typically 
75-1 x 106 cells per plate were recovered from cultures 
riched for APe. When TGF-(31 was added for the last 3 
ys of culture. similar number of cells were recovered. dem-
strating that TGF-(31 had no adverse effect on the viability 
the cultured cells. Geisma-stained cytocentrifuge prep-
Hions revealed that the APC-enriched population resembled 
lis reported previously in GM-CSF-stimulated liquid cul-
-es.:021 The morphologic appearance of the cells (approx. 
-70% macrophages and 20-30% dendritic cells) was not 
-"ected by 3 days of exposure to TGF-(3. 
fects of TGF-f31 on the phenotype of cultured 
hole BM and GM-CSF-stimulated 8M-derived 
:>C 
r purposes of comparison with cultured cells. flow cytome-
was performed on samples of freshly isolated BM cells 
,m seven cadaveric donors. These cells expressed the leuko-
te common antigen CD45. The incidence of the T cell mark-
; CD3, CD4 and CD8 was low, as was that of the B cell 
lrker, CD 19. and HLA-DR (MHC class II). There was also 
low incidence of cells expressing the monocyte marker 
)14; NK cell (CD56) and dendritic cell (COla) markers 
·re also identi tied. The adhesion molecules CD I I a, CD II b, 
.msp/anl I mmun%gy 1996: 4: 186-191 
COl8 and CD54 (rCAM-I) were all expressed on up to 50% 
of the cells. C02 and COlic were not detected. B7-1 (CD80) 
expression was very low. After 3-5 days of culture in GM-
CSF, there were no significant differences in the percentages 
of whole BM cells staining for each of these markers either 
between samples or in comparison to fresh BM. In addition, 
cells incubated in GM-CSF. and with qdc-~ I added for the 
last 3 days of culture. exhibited a phenotype similar to that of 
cells grown in GM-CSF alone (data not shown). 
The results of FACScan analysis of the APC-enriched BM-
derived cells are presented in Table I. The putative APC 
showed a comparatively high incidence of C045· and HLA-
DR· cells,. As anticipated from the morphologic appearance of 
the cells. B cell, T cell and NK cell markers were very low. 
The incidence of cells expressing the monocyte marker CO 14, 
however, was relatively high, and staining was comparatively 
bright compared to cells from whole bone marrow. Both the 
incidence and staining intensity of cells expressing the den-
dritic cell marker COla was low. The adhesion and costimu-
latory molecule CD54, however, was present on most of the 
APC population. B7-1 was found on only a small proportion of 
the cells. Similar observations on GM-CSF-stimulated human 
blood-derived cells have recently been reported.2o•21 As with 
whole BM cells, the addition of qdc-~ I during the final 3 
days of culture did not affect the cell surface phenotype of the 
APC-enriched population, although there was a trend towards 
lower percentages of cells expressing CD I a and B7-1. 
AlIostimulatory activity of 8M-derived APC 
Cultures of whole BM cells and those enriched for APC were 
tested as stimulators in one-way primary MLR (Figure I). 
Donor sp!enocytes from cryopreserved cell suspensions were 
used as control allogeneic stimulators. As shown in Figure I, 
whole 8M cells were poor stimulators of allogeneic T cells 
when compared to splenocytes. In contrast, GM-CSF-stimu-
lated BM-derived APC were consistently three to five times 
more potent than spleen cells at inducing T cell proliferation. 
At low relative stimulator cell numbers, at which spleen cells 
could no longer induce T cell proliferation, the APC exhibited 
marked allostimulatory activity. 
Table 1 Expression of cell surface antigens by TGF-J3I·treated BM-
derived APe 
Antigen GM-CSF only GM-CSF + TGF-J31 
% positive" MFlh % positive" MFlb 
CD45 57.7 (46-70) 33.8 63.6 (29-64) 46.0 
HLA-OR 48.9 (29-80) 136.6 42.3 (38-.64) 135.3 
CD) 3.5 (0-7.1) 9.1 2.2 (1.7-7.1) 7.5 
COl9 0.6 (0.1-3.5) 6.8 2.3 (0-2.4) 12.0 
COl4 62.7 (53-79) 140.5 61.4 (57-65) 113.0 
COla 16.9 (5.8-43) 12.8 8.4 (7.2-22) 11.6 
CD54 89.0 (84-92) 168.8 83.8 (77-90) 184.0 
B7·1 11.6(0-16) 19.1 2.5 (2.3-1 I) 19.1 
'Values shown are median values of the percentage of positively staining 
cells determined in cultures from 3-7 bone marrow donors. Ranges are 
shown in parentheses. 
"Mean fluorescence imensllY of cells. 
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Figure 1 Six day primary MLR showing allogeneic T lymphocyte 
activation in response to three different stimulator cell populations. 
Eleven to 17 day GM-CSF-stimulated APC were better stimulators of 
naive allogeneic T cells than spleen cells from the same donor. In 
contrast. 3-5 day GM-CSF-stimulated whole BM cells were poor 
stimulators of the MLR. Vertical bars denote standard deviations of 
the mean. Results are representative of four separate experiments 
The effects of TGF·IH on the aUostimulatory 
activity of 8M-derived APe in primary MLR 
When TGF-f31 was added for the last 3 days to 3-5 day cul-
tures of whole BM, no significant effect was observed on the 
already low allostimulatory activity of these cells (Figure 2). 
However. when TGF-f31 was added to the Ape-enriched 
population during the last 3 days of 11-17 day cultures. a 
pronounced inhibitory effect on their potent allostimulatory 
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Figure 2 Primary MLR demonstrating the allostimulatory activity of 
GM-CSF-stimulated whole 8M cells (3-5 day cultures) pretreated with 
TGF-(3I. TGF-(31 treatment of the cells did not affect their 
allosllmulatory activity. Vertical bars denote standard deviations of the 
mean. Results are representative of at least three experiments 
function was observed (Figure 3A). The effect was not seen 
if the TGF-f31 was withheld until the last 24 h of culture (data 
not shown) . 
Since it was conceivable that TGF-f31 'carried over' with 
pretreated stimulator cells could have contributed to the inhibi· 
tory effect observed, supernatants from TGF-j3I-treated cul-
tures were tested for inhibitory activity in MLR. They were 
found to have no effect on T cell proliferation in response to 
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Figure 3 (A) MLR demonstrating the effect of qdc-~f pretreatment 
of 8M-derived APC (11-17 day cultures) on their allostimulatory 
activity in primary MLR. TGF-(31 treatment for the last 3 days of 
culture reduced the subsequent allostimulatory activity of the APC. 
Standard deviations are displayed as vertical bars. (B) PL T showing 
the effects of TGF·!31 pretreatment on the stimulatory activity of APC 
cultured with primed T lymphocytes in a secondary response. TGF-
(31 reduced the allostimulation by the APC. Results are representative 
of at least three experiments 
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'nor spleen cells (data not shown). This implies that the loss 
allostimulatory activity was a result of a direct effect of 
JF-l3l on the APC, rather than to a 'carry over' effect of 
:iF-131 on the responder T cells. 
fects of TGF-131 on the stimulatory activity of 
?C for primed T lymphocytes 
Ie APC-enriched GM-CSF-stimulated cells (11-17 days of 
Iture) were tested for their ability to stimulate T cells that 
d been previously primed by a pooled panel of HLA anti-
ns. As in the primary MLR, TGF-l3l reduced the allostimul-
)ry capacity of the APC, again by about 50% (Figure 38). 
iscussion 
Jere have been few reports of the effects of TGF-13 on the 
<lction of APC. It has been shown, however, that TGF-f3 
libits antigen presentation by peripheral blood mononuclear 
ils and cultured Langerhans cells, but not by freshly isolated 
ngerhans cells.:J TGF-j3 has been implicated in endowing 
lcrophages with the capacity to induce antigen-specific 
mune deviation,"4 whereas it did not suppress tumor 
munity conferred by epidermal APC.2s 
In the present experiments, the allostimulatory capacity of 
10ie 8M cells was not affected by TGF-f3I. As its allostimu-
ory activity was initially much lower than that of the GM-
;F-stimulated APC-enriched population, whole 8M may 
ve contained insufficient numbers of TGF-13 responsive 
~C to exhibit an effect. The antigen-presenting capability of 
~ latter cells, however, appears to be markedly diminished by 
posure to TGF-j3I. The mechanism of this action is unclear. 
though the overall viability of the cells was not influenced, 
? quantities of specific cell types may have been altered by 
jF-j3I, even though no significant differences were detected 
flow cytometric analysis. Relatively small changes in the 
mbers of potent APC, such as dendritic cells, which were 
t detected by flow cytometry, may have profound effects 
the MLR. Although there was a trend towards fewer cells 
pressing the dendritic cell marker CD I a with TGF-j31 treat-
~ntI this was not statistically significant. Mature dendritic 
lis are known to be potent stimulators of naive T cells. 26 
Ierefore. relatively small changes in their numbers may have 
:lfound effects on the MLR. Macrophages and activated 8 
lis also possess the ability to stimulate T cells, although to 
nuch lesser degree than dendritic cells. The immunostimula-
~y activity of each of these cells correlates with the level 
cell surface expression of MHC class II and costimulatory 
Jlecules. IJ.14 Their comparative accessory function is not so 
ikingly different in the stimulation of primed T cell second-
I allogeneic responses, probably due to a less stringent 
iuirement for MHC class II involvement.27 The effects of 
:;F·j3l on the APC used in the PL T were nevertheless quite 
lpressive. As suggested by the present results, TGF-j3l may 
ert its influence by means other than altering the expression 
\'!HC class II. Since TGF·j3 is known to inhibit cytokine 
oduction. it may attenuate the function of APC by sup-
ession of one or more cytokine signals. 
Costimulatory molecule expression was not changed sig-
ricantly by qdc-~ I when considering the APC as a whole, 
cept for a trend towards lower 87-1 expression. This may 
:ve contributed. in part, to the loss of allostimulatory capacity 
the APC. However, detailed analysis of individual cell types 
was not performed. Conceivably, TGF-f3 may increase 
costimulatory molecule expression on some cell types, while 
simultaneously decreasing expression of the same molecules 
on others. Such an effect could disrupt the second signal 
necessary for activating T cells. 
TGF-j3 can induce autocrine secretion. ,·3.6 However, in our 
experiments, supernatants from washed APC did not affect the 
proliferation assays. Even so, the addition of APe secreting a 
continuously low level of TGF-j3, or the presence of a latent 
form of qdc-~ which later becomes activated in prolonged 
cultures, cannot be ruled out. TGF-j3 may have an effect on 
feedback received by the APC upon interaction with T cells. 
A third and a fourth signal in antigen presentation and T cell 
activation have been proposed.28 Thus, T cell interaction with 
MHC class II molecules may activate APC, resulting in 
improved costimulatory activity. T cell secreted cytokines, 
such as IL-4. may also affect APC surface molecule expression 
and function. TGF-13 may have an impact on signal transduc-
tion pathways involved in the processing of these third and 
fourth signals. 
The ability of TGF-13 (at concentrations substantially below 
those encountered in inflammatory conditions29) to inhibit the 
antigen-presenting capacity of accessory cells may have far-
reaching clinical implications. It has been suggested that 
stimulation of TGF-j3 production by T cells may, in part, 
underlie the therapeutic efficacy of cyclosporin A.2•JO TGF-r3 
prolongs heart allograft and pancreatic islet xenograft survival 
in rats. lion It also reduces the severity of experimentally 
induced allergic encephalomyelitisJJ and arthritis.J4 Moreover, 
it may be responsible for the postulated 'veto' function 
(inactivation/deletion of cytotoxic T cell precursors) of a donor 
8M-derived population that can promote the induction of 
transplant tolerance in primates.JS Augmentation of the accept-
ance of solid organ transplants with 8M infusion is being 
attempted in several centers.IS.16.J6 Cytokines such as TGF-i3 
produced constitutively or as the result of gene transfer17 may 
influence significantly the allostimulatory activity of the trans-
planted cells and the host-donor immunologic interaction. 
Further studies, particularly observations in animal models, 
will indicate the potential clinical significance of TGF-j3 for 
the therapy of allograft rejection. 
Acknowledgements 
We thank Mr Del McCaslin and Ms Frances Chambers for 
skilled technical assistance and Ms Shelly Conklin for sec-
retarial support. The work was supported, in part, by National 
Institutes of Health Grant DK 29961-13 and the Competitive 
Research Fund of the University of Pittsburgh Medical Center. 
References 
Derynck R. Transforming growth factor-beta. In: Thomson AWed. 
The cytokine handbook. second edition. San Diego; Academ ic 
Press. 1994: 319-42. 
2 Roberts AB. Sporn MB. Physiological actions and clinical appli-
cations of transformmg growth factor-[3 (TGF-!3). Growth Factor.,· 
1993; 8: 1-9. 
:1 Wahl SM. McCartney-Francis N. Mergenhagen SE. Innammatory 
and immunomodulatory roles of TGF-beta. /mmu//()/ Today 1989; 
10: 258-61. 
4 Ruscetti F. Varesio L. Ochoa A. Ortaldo J. Pleiotropic effects of 
transformmg growth factor-beta on cells of the immune system. 
AIIII NY Ac:ad Sd 1993; 685: 488-500. 
.1.51 
.1." 
.1$1 
..... 
.1<11 
.l<IZ 
J6.J 
.IM 
.1M 
.166 
.1<\1 
..... 
.\(H 
.170 
,,'7, 
-'7.1 
"4 
In 
J76 
.117 
.\711 
.179 
.100 
Ja" 
"1 
;114 
.I*, 
IKN 
' .. 
I", 
.191 
Ion 
.1'16 
.197 
I"" 
..... 
.12 
" .. 
" .. 
" .. 
TGF-f31 impairs human bone marrow-derived APe junction 191 
~ontana A. Constam DB. Frei K. Malipiero U. Pfister HW. Modu-
ation of the immune response by transfonning growth factor bela. 
'nt Arch AlIerf(Y Immunol 1992; 99: 1-7. 
<ehrl JH. Transfonning growth factor-beta: an important mediator 
)f immunoregulation. Int J Cell Cuming 1991; 9: 438-50. 
~ook AH. Kehrl lH. Wakefield LM et al. Effects of tmosfonning 
~rowth factor beta on the functions of natural killer cells; depressed 
:ytolytic activity and blunting of interferon responsiveness. J 
mmunoi 1986; 136: 3916-20. 
<:ehrl JH. Taylor A. Kim SJ. Fauci AS. Transfonning growth fac-
or-~ is a potent negative regulator of human lymphocytes. Ann 
Vy Acad Sci 1991; 628: 345-53. 
;myth MJ. Strobl SL. Young HA. Ortaldo JR. Ochoa AC. Regu-
ation of Iymphokine-activated killer activity and pre-fonning pro-
ein gene expression in human peripheral blood CD8+ T Iympho-
:ytes. Inhibition by transforming growth factor-beta. J Immunol 
,991; 146: 3289-97. 
:::zamiecki CWo Chiu HH. Wong GH. McCabe SM. Palladino MA. 
rransfonning growth factor-beta I modulates the expression of 
:Iass II histocompatibility antigens on human cells. J Immunoi 
988; 140: 4217-23. 
:spevik T. Figari IS. Shalaby MR et al. Inhibition of cytokine 
1roduction by cyclosporin A and transfonning growth factor beta. 
, up Med 1987; 166; 571-76. 
~sunawaki S. Sporn M. Ding A. Nathan C. Deactivation of macro-
lhages by transfonning growth factor· beta. Nature 1988; 334: 
:60-62. 
v1cCluskey J. Blok R. Brooks A. Chen W. Kanost D. Kjer-Nielsen 
". The biology of antigen processing and presentation. In: McClus-
:ey Jed. Antigen pmces~Ding and recognition. Boca Raton: CRC 
'ress. 1991: I-54. 
Jnanue ER. Macrophages. antigen-presenting cells. and the 
lhenomena of antigen handling and presentation. In: Paul WE ed. 
7 undamental immunology. New York: Raven Press. 1993: 111-44. 
°ontes p. Rao AS. Demetris Al et al. Bone marrow augmentation 
)f donor·cell chimerism in kidney. liver. heart. and pancreas islet 
ransplantation. Lancet 1994; 344: 151-55. 
;tanl TE. Demetris Al. Trucco M et al. Cell migration and chimer-
sm after whole·organ transplantation: the basis of graft acceptance. 
fepatoloKY 1993; 17: 1127. 
;teinman RM. Inaba K. Austyn 1M. Donor-derived chimerism in 
eClpients of organ transplants. Hepawlogy 1993; 17: 1153-56. 
~homson AW. Lu L. Murase N. Demetris AJ, Rao AS. Stanl TE. 
v1icrochimerism. dendritic cell progenitors and transplantation tol-
'rance. Stem Cells 1995; 13: 622-39. 
naba K, Inaba M. Romani N et al. Generation of large numbers 
)1 dendritic cells from mouse bone marrow cultures supplemented 
vith granu locytclmacrophage colony-stimulating factor. J Exp Med 
992; 176: 1693-702. 
:aux c. Dezutter·Dambuyant D, Schmitt D. Banchereau J. GM-
:SF and TNF-cx cooperate in the generation of dendritic Langer-
lans cells. Nature 1992; 360: 258-61. 
,allusto F. Lanzavecchia A. Efficient presentation of soluble anti-
;en by cultured human dendritic cells is maintained by 
;ranulocyteJmacrophage colony-stimulating factor plus interleukin 
+ and downregulated by tumor necrosis factor ex. J up Med 1994; 
179: 1109-18 . 
• ' .. -~ •• _ ... I .... ,..". 100.<:. t. !o,:. 101 
22 Lu L. Woo J. Rao AS et al. Propagation of dendritic cell progeni-
tors from nonnal mouse liver using granulocyte/macrophage col-
ony-stimulating factor and their maturational development in the 
presence of type-I collagen. J Exp Med 1994; 179: 1823-34. 
23 Demidem A. Taylor JR. Grammer SF. Streilein JW. Comparison 
of effects of transfonning growth factor-beta and cyclosporin A on 
antigen-presenting cells of blood and epidennis. J Invest Dermatoi 
1991; 96: 401-407. 
24 Wilbanks GA. Streilein JW. Fluids from immune privileged sites 
endow macrophages with the capacity to induce antigen-specific 
immune deviation via a mechanism involving transfonning growth 
factor-(l. EurJ Immuno/l992; 22: 1031-36. 
25 Grabbe S. Bruvers S. Granstein RD. Interleukin lex but not trans-
fonning growth factor ~ inhibits tumor antigen presentation byepi-
dennal antigen-presenting cells. J Inve.rt DermalOi 1994; 102: 
67-73. 
26 Steinman RM. The dendritic cell system and its role in immuno-
genicity. AIIIIU Rev Immu//oi 1991; 9: 271-96. 
27 Thomas R. Davis LS. Lipsky PE. Comparative accessory cell func-
tion of human peripheral blood dendritic cells and monocytes. J 
Immunol 1993; lSI: 6840-52. 
28 Hart DNJ. Calder VL. Human dendritic cells: function and cytok-
ine production, In: Bruijnzeel-Koomen CA. Hoefsmit FC cds. 
Immullflpharmacol(}gy of macrnphaoeK~ alld other antif(en-pre-
selltinR ~·e//sK San Diego: Academic Press. 1994: 63-91. 
29 Fava R, Olsen N, Keski-Oja J. Moses H. Pincus T. Active and 
latent forms of TGF-beta activity in synovial effusions. J Exp Med 
1989; 169: 291-96. 
30 Li B. Sehajpal PK. Khanna A et al. Differential regulation of trans-
fonning growth factor f3 and interleukin 2 genes in human T cells: 
demonstration by usage of novel competitor DNA constructs in 
the quantitative polymerase chain reaction. J Exp Med 1991: 174: 
12S9-Q2. 
31 Raju GP, Belland SE. Eisen HJ. Prolongation of cardiac allograft 
survival with transfonning growth factor-(ll in rats. Transplan-
tation 1994; 58: 392-96. 
32 Carel JC. Sheehan KC. Schreiber RD. Lacy PE. Prevention of 
rejection of transfonning growth factor beta-treated rat-to-mouse 
islet xenografts by monoclonal antibody to ntmor necrosis factor. 
Tran.vplantatinn 1993; 55: 456-58. 
33 Kuruvilla AP, Shah R. Hochwald GM, Liggill HD. Palladino MA. 
Thorbecke GJ. Protective effect of transfonning growth factor beta 
I on experimental autoimmune diseases in mice. Proc Natl Acad 
Sci USA 1991; 88: 2918-21. 
34 Brandes ME. Allen JB. Ogawa Y. Wahl SM. Transfonning growth 
factor beta I suppresses acute and chronic arthritis in experimental 
animals. J eli" IlIve,l't 1991: 87: 1108-13. 
35 Verbanac KM. Carver FM. Haisch CEo Thomas 1M. A role for 
transforming growth factor· beta in the veto mechanism in trans-
plant tolerance, Transplantation 1994: 57: 893-900. 
36 Barber WH, Mankin lA. Laskow DA e/ af. Long term results of 
a controlled prospective study with transfusion of donor-specific 
bone marrow in 57 cadaveric renal allograft recipients. Tran.rplan-
ta/ion 1991; 51: 70-75. 
37 Qin L. Chavin KD, Ding Yet al. Multiple vectors effectively achi-
eve gene transfer in a murine cardiac transplantation model. Tran.v-
plantation 1995; 59: 809-16. 
4711 
479 
.., 
... 
"J 
.... 
... 
.. , 
.... 
..1 
.... 
..... 
..,. 
"'2 
49.1 
-
-$00 
.\0. 
.10' 
.101\ 
S01 
lOll 
S09 
SlO 
5" 
511 
51, 
51" 
517 
51' 
'I. 
